Cargando…

Potent and rapid reversal of the von Willebrand factor inhibitor aptamer BT200

BACKGROUND: BT200, a pegylated form of the aptamer BT100, inhibits binding of von Willebrand factor (VWF) to platelet glycoprotein GPIb, preventing arterial thrombosis in cynomolgus monkeys. It is being developed for secondary prevention of arterial thrombosis such as stroke or myocardial infarction...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Shuhao, Gilbert, James C., Liang, Zicai, Kang, Daiwu, Li, Ming, Tarantino, Paul M., Jilma, Bernd
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	THROMBOSIS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7384040/ https://www.ncbi.nlm.nih.gov/pubmed/32275107 http://dx.doi.org/10.1111/jth.14822

Ejemplares similares

The development and characterization of a long acting anti‐thrombotic von Willebrand factor (VWF) aptamer
por: Zhu, Shuhao, et al.
Publicado: (2020)

The aptamer BT200 blocks von Willebrand factor and platelet function in blood of stroke patients
por: Kovacevic, Katarina D., et al.
Publicado: (2021)

The von Willebrand factor A-1 domain binding aptamer BT200 elevates plasma levels of von Willebrand factor and factor VIII: a first-in-human trial
por: Kovacevic, Katarina D., et al.
Publicado: (2021)

The aptamer BT200 effectively inhibits von Willebrand factor (VWF) dependent platelet function after stimulated VWF release by desmopressin or endotoxin
por: Kovacevic, Katarina D., et al.
Publicado: (2020)

Identification of cysteine thiol‐based linkages in ADAMTS13 in support of a non‐proteolytic regulation of von Willebrand factor
por: Rottensteiner, Hanspeter, et al.
Publicado: (2019)

Breast cancer cells mediate endothelial cell activation, promoting von Willebrand factor release, tumor adhesion, and transendothelial migration
por: Dhami, Sukhraj Pal Singh, et al.
Publicado: (2022)

Mechano-covalent protection of coagulation factor VIII by von Willebrand factor
por: Butera, Diego, et al.
Publicado: (2022)

The von Willebrand factor–binding aptamer rondaptivon pegol as a treatment for severe and nonsevere hemophilia A
por: Ay, Cihan, et al.
Publicado: (2023)

Phenotypic and genetic characterizations of the Milan cohort of von Willebrand disease type 2
por: Seidizadeh, Omid, et al.
Publicado: (2022)

Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery
por: Peyvandi, F., et al.
Publicado: (2018)

The VWF binding aptamer rondoraptivon pegol increases platelet counts and VWF/FVIII in type 2B von Willebrand disease
por: Ay, Cihan, et al.
Publicado: (2022)

Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age‐related increase of VWF in von Willebrand disease
por: Atiq, Ferdows, et al.
Publicado: (2018)

Von Willebrand disease type Vicenza: In search of a classification for the archetype of reduced von Willebrand factor survival
por: Casonato, Alessandra, et al.
Publicado: (2021)

von Willebrand factor antigen levels are associated with burden of rare nonsynonymous variants in the VWF gene
por: Sadler, Brooke, et al.
Publicado: (2021)

A conformational transition of the D′D3 domain primes von Willebrand factor for multimerization
por: Gruber, Sophia, et al.
Publicado: (2022)

Small interfering RNA–mediated allele-selective silencing of von Willebrand factor in vitro and in vivo
por: Jongejan, Yvonne K., et al.
Publicado: (2023)

Assembly of von Willebrand factor tubules with in vivo helical parameters requires A1 domain insertion
por: Javitt, Gabriel, et al.
Publicado: (2022)

A novel von Willebrand factor multimer ratio as marker of disease activity in thrombotic thrombocytopenic purpura
por: Falter, Tanja, et al.
Publicado: (2023)

Proximity proteomics identifies septins and PAK2 as decisive regulators of actomyosin-mediated expulsion of von Willebrand factor
por: El-Mansi, Sammy, et al.
Publicado: (2023)

The aptamer ARC1779 is a potent and specific inhibitor of von Willebrand Factor-mediated ex vivo platelet function in ST-elevation and non-ST-elevation acute myocardial infarction
por: Spiel, Alexander O, et al.
Publicado: (2008)

Desmopressin response depends on the presence and type of genetic variants in patients with type 1 and type 2 von Willebrand disease
por: Atiq, Ferdows, et al.
Publicado: (2022)

von Willebrand factor modulates immune complexes and the recall response against factor VIII in a murine hemophilia A model
por: Oleshko, Olga, et al.
Publicado: (2023)

Increased von Willebrand factor levels in polycythemia vera and phenotypic differences with essential thrombocythemia
por: Sacco, Monica, et al.
Publicado: (2020)

Platelet degranulation and bleeding phenotype in a large cohort of Von Willebrand disease patients
por: Swinkels, Maurice, et al.
Publicado: (2022)

Determination of von Willebrand factor level in patient with sickle cell diseasein vaso‐occlusive crisis
por: Akaba, Kingsley, et al.
Publicado: (2020)

Targeting von Willebrand Factor in Ischaemic Stroke: Focus on Clinical Evidence
por: Buchtele, Nina, et al.
Publicado: (2018)

Dynamic assessment of venous thromboembolism risk in patients with cancer by longitudinal D‐Dimer analysis: A prospective study
por: Posch, Florian, et al.
Publicado: (2020)

ADAMTS13 and von Willebrand factor assessment in steady state and acute vaso‐occlusive crisis of sickle cell disease
por: Demagny, Julien, et al.
Publicado: (2020)

The Btk inhibitor AB‐95‐LH34 potently inhibits atherosclerotic plaque–induced thrombus formation and platelet procoagulant activity
por: Smith, Christopher W., et al.
Publicado: (2022)

Aptamers Targeting Von Willebrand Factor: What and Why?
por: Schutgens, Roger E. G.
Publicado: (2023)

Milvexian, an orally bioavailable, small‐molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits
por: Wong, Pancras C., et al.
Publicado: (2021)

Hemophilia and von Willebrand disease: Factor VIII and von Willebrand factor
por: Sharma, Prashant
Publicado: (2019)

Risk of venous thromboembolism in patients with COVID‐19: A systematic review and meta‐analysis
por: Nopp, Stephan, et al.
Publicado: (2020)

Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa
por: Heitmeier, Stefan, et al.
Publicado: (2022)

Elevated plasma levels of plasminogen activator inhibitor‐1 are associated with risk of future incident venous thromboembolism
por: Frischmuth, Tobias, et al.
Publicado: (2022)

Novel inhibitor ZED3197 as potential drug candidate in anticoagulation targeting coagulation FXIIIa (F13a)
por: Pasternack, Ralf, et al.
Publicado: (2019)

The Khorana score and venous and arterial thrombosis in patients with cancer treated with immune checkpoint inhibitors: A Danish cohort study
por: Overvad, Thure F., et al.
Publicado: (2022)

Diagnostic Value of Measuring Platelet Von Willebrand Factor in Von Willebrand Disease
por: Casonato, Alessandra, et al.
Publicado: (2016)

Achieving higher efficacy without compromising safety with factor XI inhibitors versus low molecular weight heparin for the prevention of venous thromboembolism in major orthopedic surgery—Systematic review and meta‐analysis
por: Presume, João, et al.
Publicado: (2022)

Changes of von Willebrand Factor during Pregnancy in Women with and without von Willebrand Disease
por: Castaman, Giancarlo
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_41d7cc96foshjhljf137vfnfki